For four decades, an informal network of public-private partnerships has collaborated to support the advancement of the life sciences. The result has been jobs, wealth creation, improved healthcare, and prospects for new sources of energy. But those partnerships are cracking under pressure from a range of forces including constrained public budgets, the turmoil in capital markets, and the prospects of healthcare reform. Corey Goodman, former president of Pfizer's Biotherapeutics and Bioinnovation Center and an adjunct professor at the University of California, San Francisco, will be featured as a panelist at The first BioEconomy Summit, which will be held June 25 in Silicon Valley. We spoke to Goodman about the pressures on the bioeconomy, what needs to be done to make sure it continues to grow, and why policymakers should care about its future health. 

 

More information on The BioEconomy Summit can be found on the event’s website.